Core Viewpoint - A class action lawsuit has been filed against Smart Digital Group Limited, alleging securities fraud and unlawful business practices [2]. Group 1: Lawsuit Details - The lawsuit involves claims that Smart Digital and certain officers and/or directors engaged in securities fraud [2]. - Investors have until March 16, 2026, to request appointment as Lead Plaintiff if they purchased Smart Digital securities during the Class Period [2]. Group 2: Stock Price and SEC Actions - On September 26, 2025, Smart Digital's stock price dropped 86.4% to close at $1.85 per share after a trading halt by NASDAQ due to volatility [4]. - The SEC suspended trading in Smart Digital securities from September 29, 2025, to October 10, 2025, due to potential manipulation linked to social media recommendations [4]. - Following the SEC suspension, NASDAQ also suspended trading in Smart Digital securities pending further information on October 11, 2025 [4]. Group 3: Pomerantz LLP Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering multimillion-dollar damages for class members [5].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Corcept Therapeutics and its officers or directors following a significant stock price drop after the FDA's Complete Response Letter regarding relacorilant [1][3]. Group 1: Company Overview - Corcept Therapeutics Incorporated is a biopharmaceutical company focused on developing treatments for patients with conditions related to cortisol [3]. - The company’s stock price experienced a dramatic decline of $35.40 per share, or 50.42%, closing at $34.80 per share on December 31, 2025, after the FDA issued a Complete Response Letter for its New Drug Application for relacorilant [3]. Group 2: Regulatory Developments - On December 31, 2025, the FDA issued a Complete Response Letter regarding Corcept's New Drug Application for relacorilant, indicating that while the pivotal GRACE trial met its primary endpoint, additional evidence of effectiveness was required for a favorable benefit-risk assessment [3].

Core Viewpoint - Pomerantz Law Firm is investigating claims on behalf of investors of AST SpaceMobile, Inc. regarding potential securities fraud or unlawful business practices by the company and its officers or directors [2]. Group 1: Investigation Details - The investigation focuses on whether AST SpaceMobile and certain officers or directors have engaged in securities fraud or other unlawful business practices [2]. - Investors are encouraged to contact Pomerantz LLP for more information regarding the investigation [1]. Group 2: Stock Performance and Analyst Actions - On January 7, 2026, Scotiabank downgraded AST SpaceMobile to a "Sell" rating, citing significant competition from SpaceX's Starlink, slow customer adoption, and delays in launching AST's satellites [4]. - Following the downgrade, AST's stock price fell by $11.76 per share, or 12.06%, closing at $85.73 per share on the same day [4].

Core Viewpoint - Sigma Lithium Corporation is under investigation for potential securities fraud and unlawful business practices, following a downgrade by Bank of America due to unresolved operational and liquidity issues [1][3]. Group 1: Investigation and Legal Actions - Pomerantz LLP is investigating claims on behalf of Sigma Lithium investors regarding possible securities fraud or other unlawful business practices [1]. - Investors are encouraged to contact Pomerantz LLP for more information about the class action [2]. Group 2: Stock Performance and Analyst Downgrade - On January 8, 2026, Bank of America downgraded Sigma Lithium from Neutral to Underperform, citing unresolved operational and liquidity issues [3]. - Following the downgrade, Sigma Lithium's stock price decreased by $2.36 per share, or 15.07%, closing at $13.30 per share on the same day [3].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Vanda Pharmaceuticals Inc. and its officers or directors, following a negative FDA decision regarding the approval of HETLIOZ for jet lag disorder [1][3]. Group 1: FDA Decision and Market Reaction - On January 8, 2026, Vanda announced that the FDA concluded the supplemental New Drug Application for HETLIOZ could not be approved in its current form, despite acknowledging positive efficacy from clinical trials [3]. - The FDA's decision was based on the view that the clinical trial protocols did not adequately simulate actual jet travel conditions, which involve additional factors such as reduced oxygen pressure and environmental changes [3]. - Following the announcement, Vanda's stock price dropped by $1.20 per share, a decline of 14.05%, closing at $7.34 per share on the same day [3]. Group 2: Legal Investigation - Pomerantz LLP is actively investigating claims on behalf of Vanda's investors, suggesting potential legal action related to the company's business practices [1]. - Investors are encouraged to contact Pomerantz LLP for more information regarding the class action [2][6]. Group 3: Pomerantz LLP Overview - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering significant damages for victims of securities fraud and corporate misconduct [4]. - The firm has been involved in the field of securities class actions for over 85 years, continuing the legacy of its founder, Abraham L. Pomerantz [4].

Core Viewpoint - Trip.com Group Limited is under investigation for potential securities fraud and unlawful business practices, following a notice from the State Administration for Market Regulations of China regarding an anti-monopoly investigation [1][3]. Group 1: Investigation Details - Pomerantz LLP is investigating claims on behalf of investors of Trip.com, advising them to contact the firm for further information [1]. - The investigation is focused on whether Trip.com and its officers or directors have engaged in securities fraud or other unlawful business practices [1]. Group 2: Market Reaction - On January 14, 2026, Trip.com announced it received a notice of investigation from the SAMR, leading to a significant drop in its American Depositary Receipt (ADR) price, which fell by $12.90, or 17.05%, closing at $62.78 per ADR [3].

NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Aquestive Therapeutics, Inc. (“Aquestive” or the “Company”) (NASDAQ: AQST).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Aquestive and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] ...

NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Blue Owl Capital Inc. (“Blue Owl” or the “Company”) (NYSE: OWL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whether Blue Owl and certain of its ...

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving XOMA Royalty Corporation and its officers or directors [1] Group 1: Company Overview - XOMA Royalty Corporation is listed on NASDAQ under the ticker symbol XOMA [1] - The company is involved in a partnership with Rezolute, Inc. for the development of medical treatments [3] Group 2: Recent Developments - Rezolute, Inc. announced that its Phase 3 sunRIZE study evaluating ersodetug for congenital hyperinsulinism did not meet its primary endpoint, showing only a 45% reduction in hypoglycemia events at the highest dose, which was not statistically significant compared to a 40% improvement in the placebo group [3] - The study also failed to meet its key secondary endpoint, with a 25% reduction in time spent in hypoglycemia at the 10 mg/kg dose, again not statistically significant compared to a 5% increase in the placebo group [3] - Following this announcement, XOMA's stock price dropped by $7.82 per share, or 22.76%, closing at $25.39 per share on December 19, 2025 [3]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Galectin Therapeutics Inc. and its officers or directors [1] Group 1: Company Developments - On December 19, 2025, Galectin announced that the FDA provided a written response to its Type C meeting request regarding the development program for belapectin, an investigational galectin-3 inhibitor [3] - The FDA's response converted the initial request for an in-person or teleconference meeting to a written format, indicating that key aspects of the trial design remain unresolved despite alignment on the proposed patient population for a registration trial [3] Group 2: Market Reaction - Following the news of the FDA's response, Galectin's stock price fell by $1.78 per share, or 28.9%, closing at $4.38 per share on December 19, 2025 [4]